Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other solid neoplasm 1Dermatologic 1

Conditions

Multiple Myeloma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × citarinostat × Clear all
NCT02400242 2024-07-09

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Celgene

Phase 1 Terminated
85 enrolled
Plasma cell

Multiple Myeloma

NCT02635061 2024-05-07

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Celgene

Phase 1 Terminated
17 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02551185 2020-02-26

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Celgene

Phase 1 Completed
20 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT02935790 2017-08-24

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Celgene

Phase 1 Completed
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡